Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01458951 · ClinicalTrials.gov registry record · Phase 3
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis
A Phase 3 study of Ulcerative Colitis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 547
- Enrollment target
- 20
- Study locations
NCT01458951 is a Phase 3 study of Ulcerative Colitis that has completed, run by Pfizer. The registered enrollment target is 547 participants, below the 2,053-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT01458951, a Phase 3 study of Ulcerative Colitis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 547 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG tofacitinib
Study Locations (20)
California
- Alliance Clinical Research - Oceanside
- Clinical Application Laboratories - San Diego
- San Diego Endoscopy Center - San Diego
- UCSF Endoscopy Unit at Mount Zion - San Francisco
- University of California San Francisco - San Francisco
- Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center - Torrance
Florida
- Citrus Surgery & Endoscopy Center (Colonoscopy) - Crystal River
- Nature Coast Clinical Research - Inverness
- Suncoast Endoscopy Center (colonoscopy) - Inverness
- Gastroenterology Group of Naples - Naples
- Advanced Gastroenterology Center - Port Orange
- Advanced Medical Research Center - Port Orange
Connecticut
- Bristol Hospital - Bristol
- Connecticut Clinical Research Foundation - Bristol
- Yale New Haven Hospital - New Haven
- Yale University School of Medicine - New Haven
- Central Connecticut Endoscopy Center - Plainville
Arizona
- Desert Sun Clinical Research, LLC - Tucson
- Desert Sun Gastroenterology - Tucson
- Desert Sun Surgery Center - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 547 participants |
| Start Date | 2012-06 |
| Est. Completion | 2015-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01458951
The ClinicalTrials.gov registry entry for NCT01458951 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 547 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,053-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (73% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01458951 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT01458951 about?
NCT01458951 is a clinical study titled "A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis". This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha thera...
What is the current status of trial NCT01458951?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 547 participants. The study started on 2012-06. Estimated completion is 2015-06.
What conditions does trial NCT01458951 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT01458951?
The interventions under investigation include: Placebo (DRUG), tofacitinib (DRUG).
Who is sponsoring clinical trial NCT01458951?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01458951 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
RECRUITING · Phase 3
-
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RECRUITING · Phase 3
-
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
RECRUITING · Phase 3
-
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.